Speaker
Result
UV-Vis showed absorption near 280–300 nm for BNQDs and 230 nm for GO, with both features present in the hybrid. FTIR confirmed B–N stretching at 1384 cm⁻¹ alongside GO’s oxygen-containing groups. XRD showed suppression of the GO interlayer peak at about 11° after hybridization. Raman revealed GO’s D (~1350 cm⁻¹) and G (~1580 cm⁻¹) bands with B–N vibrations. SEM showed BNQDs evenly distributed over wrinkled GO sheets, giving a homogeneous nanohybrid.
Aim & Purpose
This study aimed to synthesize and characterize a graphene oxide–boron nitride quantum dot (GO-BNQDs) nanohybrid as a platform for cancer diagnosis and neutron capture therapy. Combining the boron-rich, optically active quantum dots with GO’s carrier properties could enable selective boron delivery together with imaging, addressing a limitation of BNCT.
Background
Conventional cancer therapies suffer from poor selectivity, drug resistance, and damage to healthy tissue. Boron neutron capture therapy (BNCT) kills cells locally through the boron-10 capture reaction, but its clinical use is limited by the lack of selective boron carriers. Boron nitride quantum dots and graphene oxide have each shown biomedical promise, yet their combination remains unexplored for BNCT.
Discussion (methods + interpretation)
BNQDs were synthesized hydrothermally from boric acid and ammonia (200 °C, 12 h). GO was dispersed in water by probe sonication, and the nanohybrid was formed by ultrasonication of both components at a 1:1 molar ratio, relying on non-covalent π–π stacking, electrostatic, and hydrogen-bonding interactions. The products were characterized by UV-Vis, FTIR, XRD, Raman spectroscopy, and SEM. Shifts and overlaps of the individual spectral features in the hybrid, together with the uniform distribution of quantum dots on GO sheets in SEM, were interpreted as evidence of successful interaction between BNQDs and GO.
| Email address | sundussharif7@gmail.com |
|---|---|
| Phone number | 03489925451 |